FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297460475> ?p ?o ?g. }

• W4297460475 endingPage "60" @default.
• W4297460475 startingPage "49" @default.
• W4297460475 abstract "Infliximab is a tumour necrosis factor-alpha inhibitor that is used to treat children with refractory Kawasaki disease (KD). Our purpose was to evaluate the safety and impact of infliximab versus intravenous immunoglobulins on the incidence of coronary artery aneurysms (CAAs) and treatment resistance in children with refractory KD.The Medline/PubMed, Embase, CINAHL, Cochrane Central Register of Controlled Trials and clinical trials registries were searched to December 2021. Randomized controlled trials (RCTs) comparing infliximab as second-line therapy to a second dose of intravenous immunoglobulin (IVIG) in children with refractory KD, reported in abstract or full text, were included. Studies were selected and assessed for risk of bias by two reviewers. Data were extracted and pooled using conventional random-effects meta-analysis. The certainty of evidence was assessed using the GRADE system.A total of 199 participants from four RCTs were included. The pooled risk ratio (RR) for the incidence of treatment resistance in patients treated with infliximab was 0.40 (95% confidence interval [CI] 0.25-0.64). For incidence of CAAs RR was 1.20 (95% CI 0.54-2.63), the incidence of adverse effect infusion reactions RR was 0.48, (95% CI 0.12-1.92) and for infections RR was 0.55 (95% CI 0.27-1.12). Overall, the GRADE strength of evidence for the primary outcomes was low. Evidence on the duration of fever and inflammatory biomarkers was sparse, heterogeneous and inconclusive.Moderate-certainty evidence indicates that infliximab may reduce the incidence of treatment resistance in children with refractory KD. However, the limited strength of evidence warrants further research." @default.
• W4297460475 created "2022-09-29" @default.
• W4297460475 creator A5001585828 @default.
• W4297460475 creator A5025642937 @default.
• W4297460475 creator A5040823635 @default.
• W4297460475 creator A5065857520 @default.
• W4297460475 date "2022-10-19" @default.
• W4297460475 modified "2023-10-17" @default.
• W4297460475 title "Infliximab as a second‐line therapy for children with refractory Kawasaki disease: A systematic review and meta‐analysis of randomized controlled trials" @default.
• W4297460475 cites W1648818405 @default.
• W4297460475 cites W1952578270 @default.
• W4297460475 cites W1963598954 @default.
• W4297460475 cites W1983306648 @default.
• W4297460475 cites W2023857457 @default.
• W4297460475 cites W2047539120 @default.
• W4297460475 cites W2086300194 @default.
• W4297460475 cites W2090132603 @default.
• W4297460475 cites W2134236426 @default.
• W4297460475 cites W2212818630 @default.
• W4297460475 cites W2331124118 @default.
• W4297460475 cites W2604027935 @default.
• W4297460475 cites W2771788682 @default.
• W4297460475 cites W2896176389 @default.
• W4297460475 cites W2898045891 @default.
• W4297460475 cites W2970684805 @default.
• W4297460475 cites W3118615836 @default.
• W4297460475 cites W3134705222 @default.
• W4297460475 cites W3201203055 @default.
• W4297460475 cites W4210463620 @default.
• W4297460475 cites W4232309938 @default.
• W4297460475 doi "https://doi.org/10.1111/bcp.15547" @default.
• W4297460475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36169097" @default.
• W4297460475 hasPublicationYear "2022" @default.
• W4297460475 type Work @default.
• W4297460475 citedByCount "2" @default.
• W4297460475 countsByYear W42974604752023 @default.
• W4297460475 crossrefType "journal-article" @default.
• W4297460475 hasAuthorship W4297460475A5001585828 @default.
• W4297460475 hasAuthorship W4297460475A5025642937 @default.
• W4297460475 hasAuthorship W4297460475A5040823635 @default.
• W4297460475 hasAuthorship W4297460475A5065857520 @default.
• W4297460475 hasConcept C120665830 @default.
• W4297460475 hasConcept C121332964 @default.
• W4297460475 hasConcept C126322002 @default.
• W4297460475 hasConcept C141071460 @default.
• W4297460475 hasConcept C168563851 @default.
• W4297460475 hasConcept C197934379 @default.
• W4297460475 hasConcept C2776820930 @default.
• W4297460475 hasConcept C2777138892 @default.
• W4297460475 hasConcept C2779134260 @default.
• W4297460475 hasConcept C2781423770 @default.
• W4297460475 hasConcept C44249647 @default.
• W4297460475 hasConcept C61511704 @default.
• W4297460475 hasConcept C71924100 @default.
• W4297460475 hasConcept C82789193 @default.
• W4297460475 hasConcept C95190672 @default.
• W4297460475 hasConceptScore W4297460475C120665830 @default.
• W4297460475 hasConceptScore W4297460475C121332964 @default.
• W4297460475 hasConceptScore W4297460475C126322002 @default.
• W4297460475 hasConceptScore W4297460475C141071460 @default.
• W4297460475 hasConceptScore W4297460475C168563851 @default.
• W4297460475 hasConceptScore W4297460475C197934379 @default.
• W4297460475 hasConceptScore W4297460475C2776820930 @default.
• W4297460475 hasConceptScore W4297460475C2777138892 @default.
• W4297460475 hasConceptScore W4297460475C2779134260 @default.
• W4297460475 hasConceptScore W4297460475C2781423770 @default.
• W4297460475 hasConceptScore W4297460475C44249647 @default.
• W4297460475 hasConceptScore W4297460475C61511704 @default.
• W4297460475 hasConceptScore W4297460475C71924100 @default.
• W4297460475 hasConceptScore W4297460475C82789193 @default.
• W4297460475 hasConceptScore W4297460475C95190672 @default.
• W4297460475 hasIssue "1" @default.
• W4297460475 hasLocation W42974604751 @default.
• W4297460475 hasLocation W42974604752 @default.
• W4297460475 hasOpenAccess W4297460475 @default.
• W4297460475 hasPrimaryLocation W42974604751 @default.
• W4297460475 hasRelatedWork W1793302197 @default.
• W4297460475 hasRelatedWork W1885119863 @default.
• W4297460475 hasRelatedWork W2114346778 @default.
• W4297460475 hasRelatedWork W2318187771 @default.
• W4297460475 hasRelatedWork W2531052508 @default.
• W4297460475 hasRelatedWork W2592774827 @default.
• W4297460475 hasRelatedWork W2626084264 @default.
• W4297460475 hasRelatedWork W3143600671 @default.
• W4297460475 hasRelatedWork W4212933565 @default.
• W4297460475 hasRelatedWork W4225828223 @default.
• W4297460475 hasVolume "89" @default.
• W4297460475 isParatext "false" @default.
• W4297460475 isRetracted "false" @default.
• W4297460475 workType "article" @default.